In 2024, Payers Refined Specialty Management Tactics By Taking More Active Role

Dec 12
Dec 12, 2024

As more specialty drugs and cell and gene therapies launch onto the U.S. market, payers are increasingly deploying utilization management (UM) tactics in order to focus more on targeted clinical criteria to manage them. Other strategies include shifting medical benefit drugs to the pharmacy benefit and implementing value-based contracts (VBCs). AIS Health, a division of MMIT, asked industry experts about these approaches and others that payers are taking in their management of specialty drugs for our annual look back at the year. (Editor’s note: These comments have been edited for length and clarity.) Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.